ODQ

• UNSPSC Description:

  ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells[1].

• Target Antigen:

  Apoptosis; Guanylate Cyclase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;GPCR/G Protein

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/odq.html

• Purity:

  99.63

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1ON=C2N1C3=C(C=CC=C3)N=C2

• Molecular Weight:

  187.158

• References & Citations:

  [1]Ronald Fiscus, et al. ODQ, an inhibitor of soluble guanylyl cyclase (nitric oxide-activated enzyme), enhances the pro-apoptotic effects of cisplatin in human mesothelioma cells. Cancer Res May 1 2007 (67) (9 Supplement) LB-43.|[2]Zacharowski K, et al. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med. 2001;29(8):1599-1608.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  41443-28-1